Talquetamab + teclistamab in patients with triple-class exposed R/R MM and EMD: The RedirecTT-1 study Talquetamab + teclistamab in patients with triple-class exposed R/R MM and EMD: The RedirecTT-1 study June 2025 Congress News Read more
2025 June Congress News First disclosure of epcoritamab + R-ICE in patients with R/R DLBCL eligible for ASCT: EPCORE N... Read more
2025 June Congress News Safety and efficacy of CM313 in adult patients with immune thrombocytopenia: A randomised plac... Read more
2025 June Congress News Long-term remission and survival after treatment with ciltacabtagene autoleucel in patients wi... Read more
2024 June Clinical trials First-line sintilimab with P-GemOx in advanced extranodal natural killer/T-cell lymphoma Read more
2024 June Clinical trials CAR T therapy as consolidation following ASCT in patients with high-risk lymphoma Read more
2024 May Clinical trials Remission induction vs allogeneic HSCT for patients with relapsed/poor responsive AML Read more
Top
